Company news

Creative Medical Technology Holdings, Inc. news in 2022

Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

November 2, 2022

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

October 19, 2022

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

September 25, 2022

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

July 27, 2022

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

June 14, 2022

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 28, 2022

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

April 19, 2022

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

April 11, 2022

Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform

March 30, 2022

Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study

March 22, 2022

Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction

March 9, 2022

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

March 1, 2022